NCT04824040View on ClinicalTrials.gov

Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF

Enrolling by invitationOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

February 25, 2027

Study Completion Date

July 31, 2027

Conditions

DysferlinopathyMiyoshi MyopathyLGMDR2DMAT

Trial Locations (1)

119333

Human Stem Cells Institute, Moscow

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Genotarget

INDUSTRY

lead

Artgen Biotech

OTHER

NCT04824040 - Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF | Biotech Hunter | Biotech Hunter